The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...
Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism ...
The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback